Lv2
140 积分 2024-02-22 加入
MRD-negativity after frontline DLBCL therapy: pooled analysis of 6 clinical trials
3天前
已完结
Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma
3天前
已完结
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study
3个月前
已完结
Evaluation of molecular residual disease in operable non-small cell lung cancer with gene fusions, MET exon skipping or de novo MET amplification
4个月前
已完结
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer
5个月前
已完结
皖公网安备34019202002308
